title: TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.
abstract: Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative diseases that show considerable clinical and pathologic overlap, with no effective treatments available. Mutations in the RNA binding protein TDP-43 were recently identified in patients with familial amyotrophic lateral sclerosis (ALS), and TDP-43 aggregates are found in both ALS and FTLD-U (FTLD with ubiquitin aggregates), suggesting a common underlying mechanism. We report that mice expressing a mutant form of human TDP-43 develop a progressive and fatal neurodegenerative disease reminiscent of both ALS and FTLD-U. Despite universal transgene expression throughout the nervous system, pathologic aggregates of ubiquitinated proteins accumulate only in specific neuronal populations, including layer 5 pyramidal neurons in frontal cortex, as well as spinal motor neurons, recapitulating the phenomenon of selective vulnerability seen in patients with FTLD-U and ALS. Surprisingly, cytoplasmic TDP-43 aggregates are not present, and hence are not required for TDP-43-induced neurodegeneration. These results indicate that the cellular and molecular substrates for selective vulnerability in FTLD-U and ALS are shared between mice and humans, and suggest that altered DNA/RNA-binding protein function, rather than toxic aggregation, is central to TDP-43-related neurodegeneration.
authors.affiliation: Department of Neurology and Hope Center for Neurological Diseases, Washington University School of Medicine, St Louis, MO 63110, USA.
authors.forename: Iga
authors.initials: I
authors.lastname: Wegorzewska
authors.forename: Shaughn
authors.initials: S
authors.lastname: Bell
authors.forename: Nigel J
authors.initials: NJ
authors.lastname: Cairns
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Miller
authors.forename: Robert H
authors.initials: RH
authors.lastname: Baloh
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000150:complications* / Q000473:pathology* / Q000503:physiopathology; D000818:Animals; D001921:Brain / Q000473:pathology / Q000503:physiopathology; D004268:DNA-Binding Proteins / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D004195:Disease Models, Animal; D057174:Frontotemporal Lobar Degeneration / Q000150:complications* / Q000473:pathology* / Q000503:physiopathology; D005684:Gait / Q000502:physiology; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation / Q000235:genetics*; D016019:Survival Analysis
chemical_list: D004268:DNA-Binding Proteins